{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:10:48Z","timestamp":1787019048669,"version":"build-2736575974"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this article is to review the pharmacologic and clinical profile of denosumab-bbdz (GP2411, SDZ-deno), the first interchangeable RANK ligand inhibitor biosimilar for the treatment of osteoporosis and to increase bone mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>\n                      PubMed was searched for all indexed literature published prior to January 1, 2025, using the keywords\n                      <jats:italic toggle=\"yes\">GP2411<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">SDZ-deno<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">denosumab-bbdz<\/jats:italic>\n                      . Information was also extracted from the denosumab-bbdz package insert and a gray literature search.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Phase I and III studies of the pharmacokinetic, pharmacodynamic, and clinical profile of denosumab-bbdz were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Denosumab-bbdz received Food and Drug Administration approval based on the phase I\/III ROSALIA trial which demonstrated similar pharmacokinetics, pharmacodynamics, efficacy via bone turnover rates, immunogenicity, and safety between denosumab-bbdz and reference product denosumab. Denosumab-bbdz carries a boxed warning and Risk Evaluation and Mitigation Strategy for severe hypocalcemia in patients with advanced chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Denosumab-bbdz has interchangeable status which allows substitutions without prescriber approval and reduces costs. Denosumab-bbdz assumes the same place in therapy as other denosumab products. In addition to other indications, it is a first-line option for postmenopausal osteoporosis with high or very high fracture risk after achieving equivalence in pharmacologic properties, safety, and markers for bone formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Denosumab-bbdz is the first interchangeable biosimilar for denosumab. This approval has the potential to reduce costs to patients and the healthcare system and sets an encouraging future for the potential of biosimilars.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251342581","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T01:58:10Z","timestamp":1749779890000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7011-0055","authenticated-orcid":false,"given":"Kaitlyn","family":"North","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"},{"name":"Department of Family Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6974-0810","authenticated-orcid":false,"given":"Brandi","family":"Dahl","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"},{"name":"Department of Family Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-5942","authenticated-orcid":false,"given":"KariLynn","family":"Dowling-McClay","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4625-0675","authenticated-orcid":false,"given":"McKenzie","family":"Highsmith","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA"},{"name":"Department of Family Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Food and Drug Administration. Biosimilars: overview for healthcare professionals. August 1 2024. Accessed February 23 2025. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars."},{"key":"e_1_3_2_3_2","unstructured":"Department of Health and Human Services Food and Drug Administration. Biologics Price Competition and Innovation Act of 2009.; 2010:76472-76473. Accessed February 24 2025. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-111publ148\/pdf\/PLAW-111publ148.pdf."},{"key":"e_1_3_2_4_2","unstructured":"U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Nonproprietary naming of biological products: guidance for industry. 2017. Accessed February 26 2025. https:\/\/www.fda.gov\/files\/drugs\/published\/Nonproprietary-Naming-of-Biological-Products-Guidance-for-Industry.pdf."},{"key":"e_1_3_2_5_2","unstructured":"Biosimilars Council. Suffix vs no suffix: naming biologics and biosimilars. October 21 2019. Accessed February 26 2025. https:\/\/tinyurl.com\/2566b29p"},{"key":"e_1_3_2_6_2","unstructured":"Food and Drug Administration. Purple book database of licensed biologic products. 2025. Accessed February 26 2025. https:\/\/purplebooksearch.fda.gov\/."},{"key":"e_1_3_2_7_2","unstructured":"Food and Drug Administration. Implementation of the Biologics Price Competition and Innovation Act of 2009. February 12 2016. Accessed February 26 2025. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/implementation-biologics-price-competition-and-innovation-act-2009."},{"key":"e_1_3_2_8_2","unstructured":"Association for Accessible Medicines. The U.S. Generic biosimilar medicines and savings report. 2024. Accessed February 26 2025. https:\/\/accessiblemeds.org\/wp-content\/uploads\/2025\/01\/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf."},{"key":"e_1_3_2_9_2","unstructured":"Centers for Medicare and Medicaid Services. Average sales price pricing files. 2024. Accessed February 24 2025. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files."},{"key":"e_1_3_2_10_2","unstructured":"Food and Drug Administration. FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer. 2024. Accessed February 26 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and."},{"key":"e_1_3_2_11_2","unstructured":"Sandoz Group AG. Sandoz receives FDA approval for first and only denosumab biosimilars. May 3 2024. Accessed February 23 2025. https:\/\/www.us.sandoz.com\/sandoz-receives-fda-approval-first-and-only-denosumab-biosimilars\/."},{"key":"e_1_3_2_12_2","unstructured":"Bikle D. Agents that affect bone mineral homeostasis. In: Vanderah T ed. Katzung\u2019s Basic Clinical Pharmacology. 16th ed. McGraw-Hill;2024. Accessed February 19 2025. https:\/\/accesspharmacy.mhmedical.com\/content.aspx?bookid=3382&sectionid=281754347."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae016"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2308645"},{"key":"e_1_3_2_15_2","unstructured":"Prolia (denosumab) injection [package insert]. Thousand Oaks CA: Amgen; 2010. Accessed February 26 2025. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Prolia\/prolia_pi.pdf."},{"key":"e_1_3_2_16_2","unstructured":"Jubbonti (denosumab-bbdz) injection [package insert]. Princeton NJ: Sandoz; 2024. Accessed February 20 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761362s001lbl.pdf."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.08.007"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7958"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S124476"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524SUPPL"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1891\/9780826150356"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05676-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-015-0677-z"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3535-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02401-0"},{"key":"e_1_3_2_28_2","unstructured":"National Institutes of Health Office of Dietary Supplements. Calcium fact sheet for healthcare professionals. National Institutes of Health. July 24 2024. Accessed February 26 2025. https:\/\/ods.od.nih.gov\/factsheets\/Calcium-HealthProfessional\/."},{"key":"e_1_3_2_29_2","unstructured":"PROLIA. Merative Micromedex RED BOOK. 2025. Accessed February 26 2025. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/6BF25E\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/845416\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=PROLIA&searchType=redbookProductName&searchTermId=38072&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Eprolia."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251342581","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251342581","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251342581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:09Z","timestamp":1777374849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251342581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/10600280251342581"],"URL":"https:\/\/doi.org\/10.1177\/10600280251342581","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}